Login to Your Account



Gilead, Pharmacyclics to Benefit?

Higher Death Rate Prompts Halt in Revlimid CLL Trial

By Jennifer Boggs
Managing Editor

Thursday, July 18, 2013
Analysts remained relatively unconcerned following Celgene Corp.'s news that it halted a Phase III study testing Revlimid in front-line elderly B-cell chronic lymphocytic leukemia due to an imbalance in the number of deaths between the Revlimid and control arms, though up and coming competitors could benefit from the minor setback.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription